BioMarin Pharmaceutical Inc

BMRN: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
MHLOCK|j&??@LOCK|^%<?w#

BioMarin Earnings: Voxzogo Momentum and Pipeline Expansion Support Long-Term Growth

BioMarin delivered $1 billion in third-quarter revenue, up 32% year over year, driven by 44% growth in its metabolic conditions portfolio and 12% growth from achondroplasia therapy Voxzogo. Management narrowed the midpoint of its 2026 revenue outlook by 128 basis points to $3.85 billion.

Sponsor Center